Trials / Unknown
UnknownNCT03076372
A Study Evaluating MM-310 in Patients With Solid Tumors
A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed.
Conditions
- Solid Tumors
- Urothelial Carcinoma
- Gastric Carcinoma
- Squamous Cell Carcinoma of the Head and Neck
- Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma
- Prostate Adenocarcinoma
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer
- Triple Negative Breast Cancer
- Endometrial Carcinoma
- Soft Tissue Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-310 | MM-310 |
Timeline
- Start date
- 2017-02-22
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2017-03-10
- Last updated
- 2018-02-27
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03076372. Inclusion in this directory is not an endorsement.